|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI
|
|
2
|
Akinyemiju T, Abera S, Ahmed M, Alam N,
Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y,
Artaman A, et al Global Burden of Disease Liver Cancer
Collaboration, : The burden of primary liver cancer and underlying
etiologies from 1990 to 2015 at the global, regional, and national
level: Results from the global burden of Disease Study 2015. JAMA
Oncol. 3:1683–1691. 2017.PubMed/NCBI
|
|
3
|
Njei B, Rotman Y, Ditah I and Lim JK:
Emerging trends in hepatocellular carcinoma incidence and
mortality. Hepatology. 61:191–199. 2015.PubMed/NCBI
|
|
4
|
Wang H, Lu Z and Zhao X: Tumorigenesis,
diagnosis, and therapeutic potential of exosomes in liver cancer. J
Hematol Oncol. 12:1332019.PubMed/NCBI
|
|
5
|
Chok KS, Ng KK, Poon RT, Lo CM and Fan ST:
Impact of postoperative complications on long-term outcome of
curative resection for hepatocellular carcinoma. Br J Surg.
96:81–87. 2009.PubMed/NCBI
|
|
6
|
Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia
J, Blumgart LH and DeMatteo RP: Resection of hepatocellular
carcinoma in patients otherwise eligible for transplantation. Ann
Surg. 238:315–321, discussion 321–323. 2003.PubMed/NCBI
|
|
7
|
Riaz A, Miller FH, Kulik LM, Nikolaidis P,
Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, et
al: Imaging response in the primary index lesion and clinical
outcomes following transarterial locoregional therapy for
hepatocellular carcinoma. JAMA. 303:1062–1069. 2010.PubMed/NCBI
|
|
8
|
Riaz A, Ryu RK, Kulik LM, Mulcahy MF,
Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH,
et al: Alpha-fetoprotein response after locoregional therapy for
hepatocellular carcinoma: Oncologic marker of radiologic response,
progression, and survival. J Clin Oncol. 27:5734–5742.
2009.PubMed/NCBI
|
|
9
|
Hawkins MA and Dawson LA: Radiation
therapy for hepatocellular carcinoma: From palliation to cure.
Cancer. 106:1653–1663. 2006.PubMed/NCBI
|
|
10
|
Palmer DH: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:2498, author reply
2498–2499. 2008.
|
|
11
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH III, et
al: Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502.
2017.PubMed/NCBI
|
|
12
|
Voutsadakis IA: PD-1 inhibitors
monotherapy in hepatocellular carcinoma: Meta-analysis and
systematic review. Hepatobiliary Pancreat Dis Int. 18:505–510.
2019.PubMed/NCBI
|
|
13
|
Machnicka MA, Milanowska K, Osman Oglou O,
Purta E, Kurkowska M, Olchowik A, Januszewski W, Kalinowski S,
Dunin-Horkawicz S, Rother KM, et al: MODOMICS: A database of RNA
modification pathways - 2013 update. Nucleic Acids Res.
41:D262–D267. 2013.PubMed/NCBI
|
|
14
|
Dominissini D, Moshitch-Moshkovitz S,
Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K,
Jacob-Hirsch J, Amariglio N, Kupiec M, et al: Topology of the human
and mouse m6A RNA methylomes revealed by m6A-seq. Nature.
485:201–206. 2012.PubMed/NCBI
|
|
15
|
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang
L, Jia G, Yu M, Lu Z, Deng X, et al: A METTL3-METTL14 complex
mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem
Biol. 10:93–95. 2014.PubMed/NCBI
|
|
16
|
Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang
Y, Yi C, Lindahl T, Pan T, Yang YG, et al: N6-methyladenosine in
nuclear RNA is a major substrate of the obesity-associated FTO. Nat
Chem Biol. 7:885–887. 2011.PubMed/NCBI
|
|
17
|
Bartosovic M, Molares HC, Gregorova P,
Hrossova D, Kudla G and Vanacova S: N6-methyladenosine demethylase
FTO targets pre-mRNAs and regulates alternative splicing and 3-end
processing. Nucleic Acids Res. 45:11356–11370. 2017.PubMed/NCBI
|
|
18
|
Li Z, Weng H, Su R, Weng X, Zuo Z, Li C,
Huang H, Nachtergaele S, Dong L, Hu C, et al: FTO Plays an
Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine
RNA Demethylase. Cancer Cell. 31:127–141. 2017.PubMed/NCBI
|
|
19
|
Xu D, Shao W, Jiang Y, Wang X, Liu Y and
Liu X: FTO expression is associated with the occurrence of gastric
cancer and prognosis. Oncol Rep. 38:2285–2292. 2017.PubMed/NCBI
|
|
20
|
Zhou S, Bai ZL, Xia D, Zhao ZJ, Zhao R,
Wang YY and Zhe H: FTO regulates the chemo-radiotherapy resistance
of cervical squamous cell carcinoma (CSCC) by targeting β-catenin
through mRNA demethylation. Mol Carcinog. 57:590–597.
2018.PubMed/NCBI
|
|
21
|
Liu Y, Wang R, Zhang L, Li J, Lou K and
Shi B: The lipid metabolism gene FTO influences breast cancer cell
energy metabolism via the PI3K/AKT signaling pathway. Oncol Lett.
13:4685–4690. 2017.PubMed/NCBI
|
|
22
|
Chen M, Wei L, Law CT, Tsang FH, Shen J,
Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al: RNA
N6-methyladenosine methyltransferase-like 3 promotes liver cancer
progression through YTHDF2-dependent posttranscriptional silencing
of SOCS2. Hepatology. 67:2254–2270. 2018.PubMed/NCBI
|
|
23
|
Chen Y, Peng C, Chen J, Chen D, Yang B, He
B, Hu W, Zhang Y, Liu H, Dai L, et al: WTAP facilitates progression
of hepatocellular carcinoma via m6A-HuR-dependent epigenetic
silencing of ETS1. Mol Cancer. 18:1272019.PubMed/NCBI
|
|
24
|
Wang W, Liu L, Zhou Y, Ye Q, Yang X, Jiang
J, Ye Z, Gao F, Tan X, Zhang G, et al: Hydroxychloroquine enhances
the antitumor effects of BC001 in gastric cancer. Int J Oncol.
55:405–414. 2019.PubMed/NCBI
|
|
25
|
Chandrashekar DS, Bashel B, Balasubramanya
SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017.PubMed/NCBI
|
|
26
|
Vu LP, Cheng Y and Kharas MG: The Biology
of m6A RNA Methylation in Normal and Malignant Hematopoiesis.
Cancer Discov. 9:25–33. 2019.PubMed/NCBI
|
|
27
|
Pan Y, Ma P, Liu Y, Li W and Shu Y:
Multiple functions of m6A RNA methylation in cancer. J Hematol
Oncol. 11:482018.PubMed/NCBI
|
|
28
|
Loos RJ and Bouchard C: FTO: The first
gene contributing to common forms of human obesity. Obes Rev.
9:246–250. 2008.PubMed/NCBI
|
|
29
|
Nock NL, Plummer SJ, Thompson CL, Casey G
and Li L: FTO polymorphisms are associated with adult body mass
index (BMI) and colorectal adenomas in African-Americans.
Carcinogenesis. 32:748–756. 2011.PubMed/NCBI
|
|
30
|
Jafari Nedooshan J, Kargar S, Neamatzadeh
H, Haghighi F, Dehghani Mohammad Abadi R and Seddighi N: Lack of
association of the fat mass and obesity associated (FTO) gene
rs9939609 polymorphism with breast cancer risk: A systematic review
and meta-analysis based on case - control studies. Asian Pac J
Cancer Prev. 18:1031–1037. 2017.PubMed/NCBI
|
|
31
|
Li Y, Zheng D, Wang F, Xu Y, Yu H and
Zhang H: Expression of demethylase genes, FTO and ALKBH1, is
associated with prognosis of gastric cancer. Dig Dis Sci.
64:1503–1513. 2019.PubMed/NCBI
|
|
32
|
Li J, Han Y, Zhang H, Qian Z, Jia W, Gao
Y, Zheng H and Li B: The m6A demethylase FTO promotes the growth of
lung cancer cells by regulating the m6A level of USP7 mRNA. Biochem
Biophys Res Commun. 512:479–485. 2019.PubMed/NCBI
|
|
33
|
Huang T, Gao Q, Feng T, Zheng Y, Guo J and
Zeng W: FTO knockout causes chromosome instability and G2/M arrest
in mouse GC-1 cells. Front Genet. 9:7322019.PubMed/NCBI
|
|
34
|
Wu R, Liu Y, Yao Y, Zhao Y, Bi Z, Jiang Q,
Liu Q, Cai M, Wang F, Wang Y, et al: FTO regulates adipogenesis by
controlling cell cycle progression via m6A-YTHDF2 dependent
mechanism. Biochim Biophys Acta Mol Cell Biol Lipids.
1863:1323–1330. 2018.PubMed/NCBI
|
|
35
|
Rong ZX, Li Z, He JJ, Liu LY, Ren XX, Gao
J, Mu Y, Guan YD, Duan YM, Zhang XP, et al: Downregulation of fat
mass and obesity associated (FTO) promotes the progression of
intrahepatic cholangiocarcinoma. Front Oncol. 9:3692019.PubMed/NCBI
|
